A Phase 4 interventional study of sodium monofluorophosphate toothpaste in Gingivitis and Plaque, sponsored by Colgate Palmolive. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Colgate Palmolive · Phase 4, Interventional, and Basic science
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Gingivitis by Colgate Palmolive — 8 open to participants now, 9 under way, 5 of them phase 3. Gingivitis · Colgate Palmolive.
Among the 44 studies in Gingivitis by Colgate Palmolive, this one is the 16th largest by planned enrollment, is one of 12 that started in 2026, is one of 12 in phase 4, and was the 38th registered.
634 studies on the registry are indexed under Gingivitis; 109 are open to participants now.
Browse Gingivitis studies →8 of the 44 studies in Gingivitis by Colgate Palmolive are open now, in 5 countries. Recruiting first, the newest first:
Colgate Palmolive · Sites in Italy
Ages 18–70 · Healthy volunteers
Colgate Palmolive · Sites in Germany
Ages 18–70 · Healthy volunteers
Colgate Palmolive · Sites in China
Ages 18–70 · Healthy volunteers
Colgate Palmolive
Ages 60+ · Healthy volunteers
Colgate Palmolive · Sites in Brazil
Ages 30–70
By country, each count listing its studies:
Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 66 across 510 interventional studies indexed under Gingivitis.
Median enrollment 94 across the 44 interventional studies. Of the 35 that completed or were terminated, 8 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.
5 of the studies in Gingivitis by Colgate Palmolive that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07605338Phase 3Colgate PalmoliveTo Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | 2026-11 |
| NCT07842991Phase 3Colgate PalmoliveClinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems | 2027-01 |
| NCT07842978Phase 3Colgate PalmoliveClinical Study Examining the Control of Plaque and Gingivitis | 2027-04 |
| NCT06966492Colgate PalmoliveInvestigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses. | 2027-06 |
| NCT07807397Colgate PalmoliveOral Hygiene Assistance Training Program | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Gingivitis by Colgate Palmolive, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical research study is to collect and analyze plaque and oral health measures in a population with high plaque/low gingivitis and high plaque/high gingivitis
This study is a single-arm clinical trial. Up to one hundred (100) male and female subjects who meet the inclusion/exclusion criteria will be enrolled in order to complete the study with eighty (80) subjects. Subjects will undergo oral examinations, gingival crevicular fluid collection, saliva collection, plaque collection, and will complete questionnaires. All subjects will all be supplied with a study toothbrush and toothpaste.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sodium monofluorophosphate toothpaste
All subjects will receive the same treatment for standardization
Relative abundance of Streptococcus and Porphyromonas
Comparative relative abundance of Streptococcus and Porphyromonas in sites with high plaque/low gingivitis and high plaque/high gingivitis at Visit 3
Time frame: 23-26 days
Plan to share: Undecided — Depends on the inquiry
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.
Of 25 phase 4 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 4. This study's planned 5 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.